



**First International Gliomatosis cerebri (GC) group meeting. March 26–27, 2015. Paris, France**

**Thursday March 26**

**10:30 am – 11:00 am**  
**Registration**

**11:00 am – 11:15 am**  
**Welcoming: Andres Morales**  
**Foundations and Families**

---

**11:15 am – 12:30 pm**  
**Introductory session: Jeffrey P. Greenfield**

**11:15 am – 11:45 am**  
**Title: TBD**

**11:45 am – 12:30 pm**  
**Open discussion:**

- What is the definition of GC?
- What are the signs and symptoms?
- What are the radiologic diagnostic criteria?
- What are the histologic diagnostic criteria?
- How should we establish the diagnosis?
- How relevant is obtaining tissue sampling at diagnosis?
- How relevant is obtaining tissue sampling at progression?
- Is there a “standard of care” for patients with GC?

---

**12:30 pm – 2:30 pm**  
**GC basic science session: Luis F. Parada**

**12:30 pm – 1:15 pm**  
**Title: TBD**

**1:15 pm – 2:30 pm**  
**Open discussion:**

- What regulates normal astrocyte migration and invasion in brain development?



- What are the initiating events for gliomagenesis and which are the main pathways implicated?
- Have we identified the glioma stem cell yet (and it is the same for GC as for GBM)?
- What are the current/potential biologic pathways of interest?
- What are the experiments of interest?
- What is the role of the brain cellular context for the initiation and maintenance of GC?

---

**2:30 pm – 3:00 pm**

***Lunch break***

---

**3:00 pm – 6:00 pm**

***Translational biology in GC: Mark W. Kieran***

**3:00 pm – 3:45 pm**

**Title: Applicability of DIPG/pHGG translational research approaches to GC research strategy**

**3:45 pm - 6:00 pm**

**Open discussion:**

- What are the steps we need to follow in order to uncover the genetic, epigenetic and translational events necessary for the development of GC and other invasive gliomas?
  - What molecular markers could we propose to define better this entity?
  - Are there any established cell lines that we could or should support?
  - Are there any animal models we could use as a model to follow in GC?
  - What is the list of drugs we should be considering for testing in the preclinical/clinical setting?
- 

**8 pm**

***Dinner***

---



## Friday March 27

8:30 am – 9:30 am

*The role of tissue sampling in GC: Jeffrey P. Greenfield*

8:30 am – 9:00 am

Title: TBD

9:00 am – 9:30 am

Open discussion:

- What should be the optimal surgical approach for obtaining diagnostic material in patients with suspected GC?
  - What are the minimal requirements for the tissue obtained?
  - Should we centralize the samples for analysis?
- 

9:30 am – 11:30 am

*Therapeutic implications in GC: David T.W. Jones and Chris Jones*

9:30 am – 10:30 am

Title: TBD

10:30 am – 11:30 am

Open discussion:

- Is there consensus in the diagnosis and treatment of GC?
  - Is GC more than one disease?
  - Is there a difference between pediatric and adult GC?
  - Is there a difference between patients diagnosed with primary GC vs 2<sup>nd</sup> development?
  - What can we learn from that?
  - Is there any difference based on what area of the CNS is involved?
  - Is there anything we can learn/apply from other infiltrative gliomas research discoveries (*i.e.* DIPG/GBM)?
  - What makes GC and other infiltrative glial tumors so resistant to current therapies?
  - How do these tumors acquire treatment resistance?
-



**11:30 am - 1:00 pm**

***Therapeutic implications in GC, the adults' experience: Patrick Y. Wen***

**11:30 am – 12:15 pm**

**Title : *Therapeutic implications in GC, the adults' experience***

**12:15 – 1:00 pm**

**Open discussion :**

- Is there consensus in the diagnosis and treatment of GC in the adult population?
  - What are the treatment recommendations?
  - Is GC more than one disease?
  - Is there a difference between patients diagnosed with primary GC vs 2<sup>nd</sup> development?
  - How drugs like bevacizumab can change the tumor phenotype?
  - What can we learn from that?
  - Is there any difference based on what area of the CNS is involved?
  - Is there anything we can learn/apply from other infiltrative gliomas research discoveries (*i.e.* GBM)?
  - What makes GC and other infiltrative glial tumors so resistant to current therapies? How do these tumors acquire treatment resistance?
- 

**1:00 pm – 1:45 pm**

*Lunch break*

---

**1:45 pm – 2:30 pm**

***Working towards a GC international registry: Jeffrey P. Greenfield***

**1:45 pm – 2:05 pm**

**Title: TBD**

**2:05 – 2:30 pm**

**Open discussion:**

- Would different groups support a common/shared prospective international registry?
- What can we learn from other international registries for rare diseases?
- What is the best strategy in order to collect existing samples and epidemiologic data?
- How are we going to share our data?
- How would we share data and samples in different collaborative projects?



---

**2:30 pm – 3:30 pm**

***Next Steps: Andres Morales***

Joined meeting for foundations and researchers to line out the roadmap for relevant future projects and next meeting

---

**3:30 pm – 4:30 pm**

***Fundraising and the Foundations: Speaker TBD***

- How to support international collaborative fundraising strategies?
  - Should we aim for one international foundation that leads the fundraising initiatives and directs the funds collected?
  - How to access funding for projects?
  - What can we do to help?
- 

**Addendum**

Families and foundations will hold a meeting in a separate room with the goal of finding ways to collaborate in fund raising initiatives.